

SCHWEGMAN ■ LUNDBERG ■ WOESSNER ■ KLUTH

PATENT, TRADEMARK & COPYRIGHT ATTORNEYS

P.O. Box 2938

Minneapolis, MN 55402

Telephone (612) 373-6900

Facsimile (612) 339-3061

April 1, 2003

Time: 11:30 am
(Minneapolis, Minn.)TO: Commissioner for Patents
Attn: Christopher H. Yaen
Patent Examining Corps
Facsimile Center
Washington, D.C. 20231FROM: Ann S. ViksninsOUR REF: 875.043US1TELEPHONE: (612) 373-6961FAX NUMBER (703) 746-7646Document(s) Transmitted: Draft Amendment (5 pages)Total pages of this transmission, including cover letter: 6 pgs

If you do NOT receive all of the pages described above, please telephone us at 612-373-6900, or fax us at 612-339-3061.

In re. Patent Application of: Beverly L. Davidson et al.Examiner: Christopher H. YaenSerial No.: 09/757,824Group Art Unit: 1642Filed: July 17, 1998Docket No.: 875.043US1Title: PTD MODIFIED PROTEINS

Please charge any additional fees or credit overpayment to Deposit Account No. 19-0743.

By: Ann S. Viksnins
Name: Ann S. Viksnins
Reg. No.: Reg. No. 37,748

I hereby certify that this paper is being transmitted by facsimile to the U.S. Patent and Trademark Office on the date shown below.

Ann S. Viksnins
Ann S. Viksnins1 April 2003
Date of Transmission

S/N 09/757,824PATENTIN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicant: Beverly L. Davidson et al.

Examiner: Christopher H. Yaen

Serial No.: 09/757,824

Group Art Unit: 1642

Filed: January 9, 2001

Docket: 875.043US1

Title: PTD MODIFIED PROTEINS

AMENDMENT AND RESPONSE UNDER 37 CFR § 1.116

Box AF

Commissioner for Patents

Washington, D.C. 20231

Applicant has reviewed the Office Action mailed on December 3, 2002. Please amend the above-identified patent application as follows.

This response is accompanied by a Petition, as well as the appropriate fee, to obtain a one-month extension of the period for responding to the Office Action, thereby moving the deadline for response from March 3, 2003 to April 3, 2003.

IN THE CLAIMS

1-33. [withdrawn]

34. [Currently Amended] A polypeptide comprising a non-denatured, soluble lysosomal enzyme, a naturally secreted protein, a nuclear protein, or a cytoplasmic protein operably linked to a PTD, wherein the polypeptide is expressed from an expression vector located *in situ* in a brain cell of a patient, and wherein the polypeptide is biologically active.

35. [cancelled] The polypeptide of claim 34, wherein the polypeptide is a lysosomal enzyme.

36. [Currently Amended] The polypeptide of claim 34, wherein the ~~lysosomal enzyme~~ polypeptide is a soluble lysosomal enzyme.

37. The polypeptide of claim 36, wherein the soluble lysosomal enzyme is β -glucuronidase, pepstatin insensitive protease or palmitoyl protein thioesterase.